| Cecilia Alejandra Larocca, | |
|
218 N Charles St, Apt. 1511, Baltimore, MD 21201-4021 | |
| (646) 483-8936 | |
| Not Available |
| Full Name | Cecilia Alejandra Larocca |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 12 Years |
| Location | 218 N Charles St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558688820 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 265984 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
| Dana-farber Cancer Institute, Inc. | 9133038904 | 538 |
News Archive
A new study suggests that physiological stress in premature infants combined with separation from their mothers may have lasting effects into adulthood.
Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.
Researchers at University of California San Diego School of Medicine found a significant number of children across four regions in the United States were determined to have fetal alcohol spectrum disorders.
› Verified 6 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
A new study suggests that physiological stress in premature infants combined with separation from their mothers may have lasting effects into adulthood.
Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.
Researchers at University of California San Diego School of Medicine found a significant number of children across four regions in the United States were determined to have fetal alcohol spectrum disorders.
› Verified 6 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
A new study suggests that physiological stress in premature infants combined with separation from their mothers may have lasting effects into adulthood.
Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.
Researchers at University of California San Diego School of Medicine found a significant number of children across four regions in the United States were determined to have fetal alcohol spectrum disorders.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cecilia Alejandra Larocca, 218 N Charles St, Apt. 1511, Baltimore, MD 21201-4021 Ph: (646) 483-8936 | Cecilia Alejandra Larocca, 218 N Charles St, Apt. 1511, Baltimore, MD 21201-4021 Ph: (646) 483-8936 |
News Archive
A new study suggests that physiological stress in premature infants combined with separation from their mothers may have lasting effects into adulthood.
Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.
Researchers at University of California San Diego School of Medicine found a significant number of children across four regions in the United States were determined to have fetal alcohol spectrum disorders.
› Verified 6 days ago
Sarah Nakib, MD, MPH Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Baltimore, MD 21287 Phone: 410-955-8662 | |
Elizabeth Tanzi, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-6776 | |
Crystal Ugochi Aguh, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1550 Orleans St, Crb Ii Room 211, Baltimore, MD 21287 Phone: 410-955-2400 Fax: 410-955-8645 | |
Dr. Larry H Gaston, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2300 Garrison Blvd, Suite 260, Baltimore, MD 21216 Phone: 410-945-7544 Fax: 410-945-3605 | |
Dr. Manisha J. Loss, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Suite 8060b, Baltimore, MD 21287 Phone: 410-502-2082 | |
Dr. Marcia Sanford Driscoll, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 419 W Redwood St, Suite 160, Baltimore, MD 21201 Phone: 410-328-3167 Fax: 410-328-1323 | |
Dr. Myriam Lucia Vega Gonzalez, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St # 8072, Baltimore, MD 21287 Phone: 410-955-5933 Fax: 410-502-2309 |